<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/10799A3B-C78B-4930-B3EA-AC72298BB624"><gtr:id>10799A3B-C78B-4930-B3EA-AC72298BB624</gtr:id><gtr:name>Medicines Patent Pool</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:department>Chemistry</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/10799A3B-C78B-4930-B3EA-AC72298BB624"><gtr:id>10799A3B-C78B-4930-B3EA-AC72298BB624</gtr:id><gtr:name>Medicines Patent Pool</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ED7A32FE-F06C-4485-87B4-3EECCEC75E8D"><gtr:id>ED7A32FE-F06C-4485-87B4-3EECCEC75E8D</gtr:id><gtr:name>IOTA Nano Solutions Ltd</gtr:name><gtr:address><gtr:line1>IOTA Nano Solutions Ltd</gtr:line1><gtr:line2>Mersey BIO</gtr:line2><gtr:line3>Crown Street</gtr:line3><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 7ZB</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/71BCE27E-6038-40AC-B60A-3D2746E08826"><gtr:id>71BCE27E-6038-40AC-B60A-3D2746E08826</gtr:id><gtr:name>Drugs for Neglected Dis initiative DNDi</gtr:name><gtr:address><gtr:line1>15 Chemin Louis-Dunant</gtr:line1><gtr:line4>Geneva</gtr:line4><gtr:line5>CH 1202</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/BC952C58-FC47-437C-A141-CC05BF9BDF92"><gtr:id>BC952C58-FC47-437C-A141-CC05BF9BDF92</gtr:id><gtr:firstName>Anna Maria</gtr:firstName><gtr:surname>Geretti</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3A2FA77E-6A89-4F77-9EE0-5052868D6AF1"><gtr:id>3A2FA77E-6A89-4F77-9EE0-5052868D6AF1</gtr:id><gtr:firstName>Tom</gtr:firstName><gtr:otherNames>Oliver</gtr:otherNames><gtr:surname>McDonald</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER_COI</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/82CB5BD9-215B-45DE-9EB0-07E1554FB31F"><gtr:id>82CB5BD9-215B-45DE-9EB0-07E1554FB31F</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>Owen</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/EAF39237-6F9C-4169-A3F2-E1E730173D24"><gtr:id>EAF39237-6F9C-4169-A3F2-E1E730173D24</gtr:id><gtr:firstName>Saye</gtr:firstName><gtr:surname>Khoo</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/06D51889-7867-4401-A8B5-7B573A91DB74"><gtr:id>06D51889-7867-4401-A8B5-7B573A91DB74</gtr:id><gtr:firstName>Dominic</gtr:firstName><gtr:surname>Williams</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DD82B8F7-2993-462C-B5B3-2A50A0CCA662"><gtr:id>DD82B8F7-2993-462C-B5B3-2A50A0CCA662</gtr:id><gtr:firstName>Steven</gtr:firstName><gtr:surname>Rannard</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B225E345-FAB2-4CFC-B9C1-FBE0A56A21FC"><gtr:id>B225E345-FAB2-4CFC-B9C1-FBE0A56A21FC</gtr:id><gtr:firstName>Philip</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Martin</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER_COI</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=EP%2FK002201%2F1"><gtr:id>EF50F583-BD95-465E-B283-11BA2F560911</gtr:id><gtr:title>Towards NanoMedicine Interventions for HIV/AIDS</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/K002201/1</gtr:grantReference><gtr:abstractText>Nanomedicines have proven extremely valuable in recent years and many are used daily to treat patients with a range of conditions or needs - from the treatment of cancer and menopausal symptoms to the prevention of organ rejection or malnutrition/weight loss. A range of unmet clinical needs may benefit considerably from the research and application of new nanoparticle synthesis techniques and the development of appropriate nanomedicines and provision of scale-able, commercially viable technologies that can impact patient outcomes is a key goal of nanomedicine research.

Validation of new technologies through optimisation of product performance, demonstration of pharmaceutically relevant manufacturing and in-man pharmacokinetic studies is critical for progression as is the study of nanotoxicology to establish a safety assessment that supports future investment.

To date, a series of candidate nanomedicines for HIV/AIDS treatment have been generated at the University of Liverpool in collaboration with IOTA NanoSolutions Ltd, a specialist start-up company in the UK, and supported by RCUK funding. IOTA is commercialising a novel nanoparticle synthesis technology (initially developed at UoL with EPSRC funding support) that rivals the most successful commercial top-down nanomedicine technology - nanomilling. The HIV/AIDS nanomedicine candidates have been the subject of 3 patent filings and funds are sought to optimise their production and establish their behaviour using clinical research techniques. Additionally the project will seek to dramatically increase the understanding of nanomedicine through fundamental mechanistic studies, thereby producing new insight into the mode of action and the safety of future nanomedicines.

If successful, the programme will produce the first nanomedicine options for HIV/AIDS therapy with benefits for patient care potentially including lower dosing, reduced side effects, better patient-to-patient consistency and a reduction of tablet size. Significant interest has been generated within Medecins Sans Frontiere who are keen to utilise the outputs for charitable medicines in the developing world, treating children with HIV infection with better products and prevent HIV infection in newborns. Currently, to prevent transmission of HIV to children from infected mothers, the World Heath Organisation has recommended dosing from 3 weeks after birth with antiretrovirals. The only children's medicines available include high levels of alcohol to dissolve the poorly water-soluble drugs. The nanomedcines within this programme are dispersible in water and offer a step-forward in paediatric therapy. 

The successful establishment of the fundamental research underpinning new nanomedicines will provide a clear advance in the UK's global standing in this emerging area, currently valued at &amp;gt;US$75bn and growing rapidly, with expectations to reach &amp;gt;US$100bn within 3 years.</gtr:abstractText><gtr:potentialImpactText>The key focus of the proposal is the collaborative progression of research outputs from RCUK Grand Challenge funding to demonstrated nanomedicines with the potential for further development into products and the delivery of improved patient outcomes. Critical to this is the generation of in man PK data as this validates the research by generating relevant evidence of behaviour in man rather than questionable links from animal models to human performance.

The beneficiaries of the research therefore fall into a number of groups including scientists, clinicians, patients and industry. Within the field of nanomaterials and nanomedicine, a series of ongoing societal and governmental debates are discussing the safety and application of nanoscale technologies. The programme will engage fully with this debate and provide insight and new opinion from the direct outputs of the materials, pharmacology and clinical research proposed, with the potential to impact policy decisions.
The charity M&amp;eacute;decins Sans Fronti&amp;egrave;re and the Drugs for Neglected Diseases Initiative are highly committed to evaluating the nanomedicine options for the paediatric dosing in the developing world. This holds the possibility of prevention of mother-to-child transmission as the WHO guidelines recommend a prophylactic dosing of antiretrovirals to new-borns as early as 3 weeks old and for up to 8 years. Provision of relevant formulations has been poor and new options are urgently required to prevent transmission during breastfeeding and into the later years. Adoption of the proposed research outputs in sub-Saharan Africa would impact a growing population of HIV patients and help to slow the increasing numbers of infant infections. Within developed countries, HIV nanomedicines may act to increase patient
compliance and reduce patient variability, thereby providing clinicians with therapies with more predictable clinical outcomes and consistency across varying patient populations. Also, it is a fallacy to bieve that HIV is not a concern within the developed world and can be managed as a chronic disease. Infections in teh UK continue to rise alarmingly and maintenance of patient quality of life requires a life-long commitment to a cocktail of drugs with considerable inter-patient variability and side-effects. Although the rate of infection has decreased, the numbers of new infections per year in the UK-alone are still in the thousands and multi-drug resistance (often derived from poor patient compliance) is leaving many patients with fewer therapy options.

If successful, the project will generate therapy options that will be commercially protected and have considerably demonstrated progress towards product manufacture, thereby able to generate future investment. The provision of new data and successful results in this area will show the wide applicability of the nanoparticle synthesis and resulting nanomedicine generation. The project also has the capability to secure the future of a small, high technology company in the North West, building a foundation for considerable investment and commercial revenues. It is also worth noting that outputs from the programme will potentially represent the first nano-antiretroviral commercial therapies after progression to the clinic.
As a platform for future products with a developed supply chain and demonstration of in-man pharmacokinetics, this will generate a significant commercial opportunity for the UK with multiple areas of impact.</gtr:potentialImpactText><gtr:fund><gtr:end>2016-11-13</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2012-05-14</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1333141</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Glasgow</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>English Language</gtr:department><gtr:description>EU Nanocharacterisation Laboratory</gtr:description><gtr:id>CF13E281-2518-4276-987C-4BB17D98381D</gtr:id><gtr:impact>No outputs as yet</gtr:impact><gtr:outcomeId>56b3749247f1c3.81387973-1</gtr:outcomeId><gtr:partnerContribution>Additional input from multiple EU partners to characterise candidate nanomedicines</gtr:partnerContribution><gtr:piContribution>The University of Liverpool team provide critical expertise developed through EPSRC grant funded activity, to the Horizon 2020 funded European Nanocharcterisation Laboratory</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medicines Patent Pool</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>Medicines Patent Pool</gtr:description><gtr:id>81284821-0C04-48FA-9CF5-98AB6E17DEBE</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>56b37362a96b42.40839148-1</gtr:outcomeId><gtr:partnerContribution>MPP are seeking partners for scale up and translation of clinical outputs to enable therapy scale up and charitable access</gtr:partnerContribution><gtr:piContribution>Development of prototype and clinical candidate therapies (nanomedicine) for HIV treatment</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Schools Outreach activity</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E30A0C67-186B-462F-89C1-37929BAB10BB</gtr:id><gtr:impact>Vardean College/RSC Sixth former science meeting. Engagement with 6th formers to explain current progress in Nanomedicine</gtr:impact><gtr:outcomeId>56b322c70d1e84.76443301</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Meeting with industry (Revolymer)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>30F9D5CB-36A1-4825-99FB-7DBB99C9073D</gtr:id><gtr:impact>Engagement with research activities and future licence/collaborative research opportunities</gtr:impact><gtr:outcomeId>56b32346216860.26228567</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Meetings with Medicines Patent Pool (Geneva)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>080809D5-EF87-436A-8E31-13ED5E2143E3</gtr:id><gtr:impact>Discussions to evaluate licence opportunities to allow translation of research outputs through charitable funding and generic pharma companies. MPP are UNITAID funded</gtr:impact><gtr:outcomeId>56b3246d96fb53.15368978</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Third sector organisations</gtr:primaryAudience><gtr:year>2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Princes Teaching Institute CPD</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CAB3CF97-09E9-41F0-BBE0-85FC64A25F93</gtr:id><gtr:impact>CPD for teachers. Presentation designed to update teachers with up to date information to allow teaching knowledge in Nanomedicine</gtr:impact><gtr:outcomeId>56b32187a88655.29854156</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Website for the British Society for Nanomedicine</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3FF8D38D-4083-48D9-B5C5-5AB9CC6E3D75</gtr:id><gtr:impact>As part of the creation and launch of the British Society for Nanomedicine as website has been created allowing access to information for children, schools, the public and scientists (academic and industrial)

The Society now has &amp;gt;300 members globally and has held multiple meetings</gtr:impact><gtr:outcomeId>r-143574895.470938562b83d766</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Meeting to discuss research outputs with Global Charity (Clinton Health Access Initiative)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>314933C4-D58F-4C61-9A72-A44E799E7C6F</gtr:id><gtr:impact>Activity was used to engage with the Clinton Health Access Initiative to receive support and garner interest in translational activities directed at candidate global HIV nanomedicine therapy development</gtr:impact><gtr:outcomeId>56b325a039d335.02527273</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Third sector organisations</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>87922</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIH Funding from US</gtr:description><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:id>1C1E8E4E-68FD-4CF1-BE46-2CF36BD3EE6E</gtr:id><gtr:outcomeId>r-5224501886.61413506a3977e</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>829000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Industrial Funding</gtr:description><gtr:end>2019-04-02</gtr:end><gtr:fundingOrg>Industry Partners</gtr:fundingOrg><gtr:id>7052309D-8661-4DB4-801B-90863FD013B7</gtr:id><gtr:outcomeId>58c92337dc1214.85792581</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5000000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>USAID PEPFAR ART Simplification</gtr:description><gtr:end>2020-09-02</gtr:end><gtr:fundingOrg>United States Agency for International Development</gtr:fundingOrg><gtr:fundingRef>AID-OAA-A-15-00069</gtr:fundingRef><gtr:id>AAA53C0D-4922-41A9-98CF-8F6507B570E5</gtr:id><gtr:outcomeId>56b31c9337df26.75371073</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1210035</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>US NIH R01 funding</gtr:description><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:fundingRef>R01AI114405</gtr:fundingRef><gtr:id>EFD2148B-9A9A-44B5-BD43-ABD6D5A5874A</gtr:id><gtr:outcomeId>56b31df94ea126.86825551</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>914582</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Funding for Imaging</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/K015931/1</gtr:fundingRef><gtr:id>82B19592-8F8F-43D7-9F7E-F87E26BAF931</gtr:id><gtr:outcomeId>5eded9585eded96c</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>349000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Industrial Funding - Agrochemicals</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>Industry Partners</gtr:fundingOrg><gtr:id>32C6A267-78D9-42CD-80D5-3EEA6BEFAFF3</gtr:id><gtr:outcomeId>58c922af1df164.40485299</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>87922</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIH Funding from US</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:id>F07389F6-B2AD-4800-99B0-049B77FF7F99</gtr:id><gtr:outcomeId>5ec8f03e5ec8f052</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>The outcomes of the research have generated a collaborative agreement with the UNITAID-funded Medicines Patent Pool - the first academic technology provision to MPP. The successful healthy volunteer trial has led to a tendering for industrial development partners and several have signed CDAs to access further information and detailed discussions. Calculations have shown that the potential reduced doses available could save &amp;gt;$500m in the first 5 years of adoption for global charities and offer potential easing of manufacturing pressure for the global supply chain.</gtr:description><gtr:firstYearOfImpact>2016</gtr:firstYearOfImpact><gtr:id>BBD57EE3-D239-414B-82D1-143C13C4E7E7</gtr:id><gtr:impactTypes><gtr:impactType>Societal,Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>56b378808bd525.94715328</gtr:outcomeId><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The present inventions relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drug efavirenz. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol-succinate (Vit- E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N-alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol-12-hydroxystearate, polyvinyl alcohol (PVA), and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alcohol (PVA), a polyvinyl alcohol-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl methyl cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof. The present invention also relates to processes for preparing both the solid composition and the aqueous dispersion, as well as to their use in therapy for the treatment and/or prevention of retroviral infections such as human immunodeficiency virus (HIV).</gtr:description><gtr:grantRef>EP/K002201/1</gtr:grantRef><gtr:id>771EEDA1-FF2B-4746-9BF8-5225FA4DA1B9</gtr:id><gtr:impact>Supporting human clinical trials</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>56b36f87ef1437.40219765</gtr:outcomeId><gtr:patentId>WO2013034925</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>COMPOSITIONS OF EFAVIRENZ</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drug lopinavir. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol-succinate (Vit- E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N- alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol-12-hydroxystearate, polyvinyl alcohol (PVA), and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alcohol (PVA), a polyvinyl alcohol-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl methyl cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof. The present invention also relates to processes for preparing both the solid composition and the aqueous dispersion, as well as to their use in therapy for the treatment and/or prevention of retroviral infections such as human immunodeficiency virus (HIV).</gtr:description><gtr:grantRef>EP/K002201/1</gtr:grantRef><gtr:id>D3637ECF-F395-4FF6-BC21-3D85A59A3CAF</gtr:id><gtr:impact>This patent is underpinning a human clinical trial and has attracted considerable global interest from charities and NIH (US)</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>m-9422826356.648306766748a6</gtr:outcomeId><gtr:patentId>WO2013034926</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>COMPOSITIONS OF LOPINAVIR</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present inventions relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drugs lopinavir and ritonavir. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol- succinate (Vit-E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N- alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol-12-hydroxystearate, polyvinyl alcohol (PVA), and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alcohol (PVA), a polyvinyl alcohol-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl methyl cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof. The present invention also relates to processes for preparing both the solid composition and the aqueous dispersion, as well as to their use in therapy for the treatment and/or prevention of retroviral infections such as human immunodeficiency virus (HIV).</gtr:description><gtr:grantRef>EP/K002201/1</gtr:grantRef><gtr:id>0027EF64-87F1-4B76-A211-145DD9BDFBF7</gtr:id><gtr:impact>Currently supporting human clinical trials</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>56b371865d10f0.40386700</gtr:outcomeId><gtr:patentId>WO2013034927</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>COMPOSITIONS OF LOPINAVIR AND RITONAVIR</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drug lopinavir. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol-succinate (Vit- E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N- alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol-12-hydroxystearate, polyvinyl alcohol (PVA), and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alcohol (PVA), a polyvinyl alcohol-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl methyl cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof. The present invention also relates to processes for preparing both the solid composition and the aqueous dispersion, as well as to their use in therapy for the treatment and/or prevention of retroviral infections such as human immunodeficiency virus (HIV).</gtr:description><gtr:grantRef>EP/K002201/1</gtr:grantRef><gtr:id>16A7E60C-A21E-484A-9CB7-52FC030B509F</gtr:id><gtr:impact>Currently supporting human clinical trials</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>56b37032abfd67.83936457</gtr:outcomeId><gtr:patentId>WO2013034926</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>COMPOSITIONS OF LOPINAVIR</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present inventions relates to a solid compn. and an aq. dispersion comprising nanoparticles of the antiretroviral drugs lopinavir and ritonavir. The solid compn. and aq. dispersion addnl. comprise a mixt. of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol succinate (Vit-E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N-alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol 12-hydroxystearate, polyvinyl alc., and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alc. (PVA), a polyvinyl alc.-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl Me cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof. The present invention also relates to processes for prepg. both the solid compn. and the aq. dispersion, as well as to their use in therapy for the treatment and/or prevention of retroviral infections such as human immunodeficiency virus (HIV).</gtr:description><gtr:grantRef>EP/K002201/1</gtr:grantRef><gtr:id>20B49D5B-4225-4DE8-A417-366A59BCA2AB</gtr:id><gtr:impact>Much interest in this patent application as part of a larger portfolio and negotiations to progress to human trials are ongoing</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>m-7927802631.5642557667498c</gtr:outcomeId><gtr:patentId>WO2013034927</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>COMPOSITIONS OF LOPINAVIR AND RITONAVIR</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present inventions relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drug efavirenz. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol-succinate (Vit- E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N-alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol-12-hydroxystearate, polyvinyl alcohol (PVA), and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alcohol (PVA), a polyvinyl alcohol-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl methyl cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof. The present invention also relates to processes for preparing both the solid composition and the aqueous dispersion, as well as to their use in therapy for the treatment and/or prevention of retroviral infections such as human immunodeficiency virus (HIV).</gtr:description><gtr:grantRef>EP/K002201/1</gtr:grantRef><gtr:id>8CC9E0E8-D5C6-47E4-89BB-8C130EA46443</gtr:id><gtr:impact>The patent is supporting a human clinical trial and has initiated interest from global charities and the NIH (US)</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>m-9728776486.337908766747c0</gtr:outcomeId><gtr:patentId>WO2013034925</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>COMPOSITIONS OF EFAVIRENZ</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>The formation of candidate nanomedicines for HIV therapy at the bench scale has been translated to clinical manufacturing and received MHRA approval for human testing. Healthy volunteer trials have shown the potential to reduce the oral dose of two of the leading HIV therapies by 50% whilst maintaining drug exposure levels. This is a hugely valuable outcome as it reduces the cost of therapy (estimated at &amp;gt;$500m over 5 years), offers charities the potential to provide therapy for a greater number of patients and reduces pressure on drug manufacturing and supply chains. This represents the world's first orally-dosed nanomedicine candidate for HIV therapy.</gtr:description><gtr:exploitationPathways>The healthy volunteer trials have formed the basis for translation to generic pharmaceutical scale up and progression through to global charities for distribution to affected populations. A collaboration with the UNITAID funded Medicines Patent Pool has been established (the first academic technology provider to MPP) and development partners have been identified for future scale-up and commercialisation potential. CDAs have been signed and discussions are underway to establish the most efficient way forward.</gtr:exploitationPathways><gtr:id>93F15FF1-5981-4FCB-B110-1F43F29D9D35</gtr:id><gtr:outcomeId>56b3778798d3c3.17616961</gtr:outcomeId><gtr:sectors><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors><gtr:url>https://www.eurekalert.org/pub_releases/2015-11/uol-npp113015.php</gtr:url></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Membership of Innovate UK Emerging Technologies and Industries Steering Committee</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5ED14888-AC1D-434B-9F56-3B537FA51522</gtr:id><gtr:outcomeId>56b3266716d3c3.16330175</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>This is an nanomedicine for HIV therapy aiming to dramatically reduce the dose and the overall pill burden for HIV sufferers. There is also potential for paediatric therapy development.</gtr:description><gtr:id>C6A24506-7F94-484F-833E-5C87A6505B21</gtr:id><gtr:impact>Licence agreement signed with UNITAID-funded Medicines Patent Pool (Geneva) and considerable additional funding to establish potential within other drugs for HIV (USAID multinational collaboration) and malaria (interatction with Johns Hopkins Medical School). In addition, significant engagement with Clinton Health Access Initiative and the securing of an R01 grant from NIH to study long acting HIV nanomedicines with a team from Johns Hopkins Medical School.</gtr:impact><gtr:outcomeId>56b32cf066d666.28961263</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Oral Nanomedicine for HIV using Lopinavir</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Human study of pharmacokinetics of orally dosed nanoparticles of efavirenz aiming at dose and pill burden reduction. Engagement with international charities (Clinton Health Access Initiative; Medicines Patent Pool, MSF) and further funding from NIH (collaboration with Johns Hopkins Medical School) and USAID (Multinational collaboration) to establish potential in other HIV related areas and malarial opportunities.</gtr:description><gtr:id>228F3FA2-C41C-41CE-A987-04C6014FA7CF</gtr:id><gtr:impact>Awaiting outcomes</gtr:impact><gtr:outcomeId>56b32ddd60a048.60414268</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Human trial of candidate nanomedicine for HIV using Efavirenz</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Tandem Nano Ltd</gtr:companyName><gtr:description>Tandem Nano Ltd is a nanoformulation company aiming to improve the action, delievry, use and behaviour of poorly soluble compounds</gtr:description><gtr:id>73F85467-6010-4773-A694-63276EC41A6F</gtr:id><gtr:impact>Currently negotiating meaningful interactions with numerous global companies</gtr:impact><gtr:outcomeId>545e5d71c4eb79.08211231</gtr:outcomeId><gtr:url>http://www.tandemnano.com/</gtr:url><gtr:yearCompanyFormed>2014</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>EECE10C6-B668-4739-9288-BC84569488F0</gtr:id><gtr:title>Long-acting injectable atovaquone nanomedicines for malaria prophylaxis.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0c0e804d612dc1056553eea92f53cbb"><gtr:id>e0c0e804d612dc1056553eea92f53cbb</gtr:id><gtr:otherNames>Bakshi RP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5a8c1b6fcc1986.73442993</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A31100D-5713-4D64-B4B7-A67F63547C46</gtr:id><gtr:title>Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions.</gtr:title><gtr:parentPublicationTitle>Nanomedicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/936be8fe289660558eed2b8dc4f61ee3"><gtr:id>936be8fe289660558eed2b8dc4f61ee3</gtr:id><gtr:otherNames>Liptrott NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1743-5889</gtr:issn><gtr:outcomeId>545e308eb9aca1.65331784</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC809BAE-2173-453F-A571-EA9DB67D5E38</gtr:id><gtr:title>Intracellular delivery of nano-formulated antituberculosis drugs enhances bactericidal activity</gtr:title><gtr:parentPublicationTitle>Journal of Interdisciplinary Nanomedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e7594694084df02beef8c2795d92f72"><gtr:id>8e7594694084df02beef8c2795d92f72</gtr:id><gtr:otherNames>Donnellan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a8c1c59e22fe9.10371240</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B0151A1-D280-4611-BDCC-EB4697683309</gtr:id><gtr:title>Lack of interaction of lopinavir solid drug nanoparticles with cells of the immune system.</gtr:title><gtr:parentPublicationTitle>Nanomedicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/936be8fe289660558eed2b8dc4f61ee3"><gtr:id>936be8fe289660558eed2b8dc4f61ee3</gtr:id><gtr:otherNames>Liptrott NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1743-5889</gtr:issn><gtr:outcomeId>5a8c1c5a2a4e92.40255820</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0A7F1FD-231F-4910-9FC5-5BA7BE2EDADD</gtr:id><gtr:title>In vitro characterisation of solid drug nanoparticle compositions of efavirenz in a brain endothelium cell line</gtr:title><gtr:parentPublicationTitle>Journal of Interdisciplinary Nanomedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9b85ee323b50a8e7c01e965c3546c48"><gtr:id>f9b85ee323b50a8e7c01e965c3546c48</gtr:id><gtr:otherNames>Curley P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a8c1bba26ce35.19994504</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2EC5B2E0-9D97-4E29-900B-70EC74789447</gtr:id><gtr:title>In vitro characterization of efavirenz-containing solid drug nanoparticles</gtr:title><gtr:parentPublicationTitle>ANTIVIRAL THERAPY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/151899c7dd6c7ddeaac6bd47d81d2efa"><gtr:id>151899c7dd6c7ddeaac6bd47d81d2efa</gtr:id><gtr:otherNames>King S. C.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>56b33aa038fb52.63578973</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F884B3EF-D90A-4087-B774-C519B8138B65</gtr:id><gtr:title>INVITED: Improved Oral Delivery of Antiretroviral Drugs Via A Novel Synthesis of Solid Drug Nanoparticle Formulations</gtr:title><gtr:parentPublicationTitle>Nanomedicine 2014</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf1d6d619c42388d8cdb238501bb7319"><gtr:id>cf1d6d619c42388d8cdb238501bb7319</gtr:id><gtr:otherNames>Owen A</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>545e6261ef2a38.08834525</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16B71638-22A3-463D-A5A5-0664F1FEA62F</gtr:id><gtr:title>Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy.</gtr:title><gtr:parentPublicationTitle>Advanced drug delivery reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf1d6d619c42388d8cdb238501bb7319"><gtr:id>cf1d6d619c42388d8cdb238501bb7319</gtr:id><gtr:otherNames>Owen A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0169-409X</gtr:issn><gtr:outcomeId>585d60d20c4ff8.37674763</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8262E86-4565-41EB-A553-2F9C775D7B19</gtr:id><gtr:title>Nanomedicines for HIV therapy.</gtr:title><gtr:parentPublicationTitle>Therapeutic delivery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/65da67b16bc5ccd9ce1b330b734b99ed"><gtr:id>65da67b16bc5ccd9ce1b330b734b99ed</gtr:id><gtr:otherNames>Siccardi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2041-5990</gtr:issn><gtr:outcomeId>doi_53d08908940a3cd5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A24D328-E96C-44B0-A7F4-EA762717A2CA</gtr:id><gtr:title>In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacokinetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0ec1450891985bbec1007a12730b88f"><gtr:id>d0ec1450891985bbec1007a12730b88f</gtr:id><gtr:otherNames>Rajoli RKR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0312-5963</gtr:issn><gtr:outcomeId>5a8c1b6fa83eb9.84585160</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B4CD3A6-212D-4C05-847E-0C8911A98CA8</gtr:id><gtr:title>Reactions of hydrophobic organic nanoparticle mixtures in water: nanoparticle-on-nanoparticle oxidative dye bleaching</gtr:title><gtr:parentPublicationTitle>Green Chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/236f8fefb1de42b371cef64a9fd83257"><gtr:id>236f8fefb1de42b371cef64a9fd83257</gtr:id><gtr:otherNames>Giardiello M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>56b31ae47c8a17.47259791</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8529B0BD-E5BC-4112-960A-963B2520BADA</gtr:id><gtr:title>The application of nanotechnology in medicine: treatment and diagnostics.</gtr:title><gtr:parentPublicationTitle>Nanomedicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf1d6d619c42388d8cdb238501bb7319"><gtr:id>cf1d6d619c42388d8cdb238501bb7319</gtr:id><gtr:otherNames>Owen A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1743-5889</gtr:issn><gtr:outcomeId>545e308ee01a58.66656332</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F757091-7644-4761-BE38-50953AD142F4</gtr:id><gtr:title>Simulating Intestinal Transporter and Enzyme Activity in a Physiologically Based Pharmacokinetic Model for Tenofovir Disoproxil Fumarate.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4755fe90517ba2ba3199dc82e04f781"><gtr:id>b4755fe90517ba2ba3199dc82e04f781</gtr:id><gtr:otherNames>Moss DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>5a8c1c7850a4f5.59754879</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A52669F-4D0D-43D9-9B81-A2406C2F990D</gtr:id><gtr:title>&amp;quot;Rapid &amp;quot;&amp;quot;bottom-up&amp;quot;&amp;quot; production of organic nanoparticles: From drug bioavailability enhancement to fluorescence studies of cellular accumulation&amp;quot;</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e70cb32bd30566135ed3c1a9049031cc"><gtr:id>e70cb32bd30566135ed3c1a9049031cc</gtr:id><gtr:otherNames>Marco Giardiello</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>r_4323183177cac16f8a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1C5B770-C55A-4BCC-9915-0CBA260746B2</gtr:id><gtr:title>Mediation of in vitro cytochrome p450 activity by common pharmaceutical excipients.</gtr:title><gtr:parentPublicationTitle>Molecular pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8aebd9fcdb75ba6a10430e6f39a62dd8"><gtr:id>8aebd9fcdb75ba6a10430e6f39a62dd8</gtr:id><gtr:otherNames>Martin P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1543-8384</gtr:issn><gtr:outcomeId>doi_55f953953916ad95</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E801C1C-83C5-4938-B462-8DBF761FEE2B</gtr:id><gtr:title>3rd Annual World Drug Delivery &amp;amp; Formulation Summit</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f1d0b33a9155ad878eeb3bfd94192bb"><gtr:id>5f1d0b33a9155ad878eeb3bfd94192bb</gtr:id><gtr:otherNames>Steve  Rannard (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>m_6459253978140762fa</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>683C3C9D-D0BA-4C62-9AA6-4E9ECBA965B4</gtr:id><gtr:title>Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz.</gtr:title><gtr:parentPublicationTitle>In silico pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/65da67b16bc5ccd9ce1b330b734b99ed"><gtr:id>65da67b16bc5ccd9ce1b330b734b99ed</gtr:id><gtr:otherNames>Siccardi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2193-9616</gtr:issn><gtr:outcomeId>doi_53d07c07c0292b7e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87E656D7-165E-4DB1-B765-A7E0D4A55940</gtr:id><gtr:title>INVITED: Emerging Platform Technologies for Nanotherapies</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/48459838935911b680e4543a7fab9f6d"><gtr:id>48459838935911b680e4543a7fab9f6d</gtr:id><gtr:otherNames>Rannard S P</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>545e5e9d38f774.23168638</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54C5A3EF-011C-482E-AE22-7DC35C921D34</gtr:id><gtr:title>Rapid nanoformulation and GMP preparation of antiretroviral drugs for oral HIV nanomedicines and human clinical dosing studies</gtr:title><gtr:parentPublicationTitle>Converging technology for nanobio-applications of the E-MRS 2014 Spring Meeting</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/236f8fefb1de42b371cef64a9fd83257"><gtr:id>236f8fefb1de42b371cef64a9fd83257</gtr:id><gtr:otherNames>Giardiello M</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>545e6605b98260.33442251</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B49FF72-F0AB-400B-82D7-EC1C06E52E18</gtr:id><gtr:title>Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation.</gtr:title><gtr:parentPublicationTitle>Advanced healthcare materials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0417a44a7ef591b40114351d26ff40bb"><gtr:id>0417a44a7ef591b40114351d26ff40bb</gtr:id><gtr:otherNames>McDonald TO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2192-2640</gtr:issn><gtr:outcomeId>545e308e44a921.07554244</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3F5E8A8-1916-45BB-8142-35EB9861E486</gtr:id><gtr:title>Emerging nanomedicine applications and manufacturing: progress and challenges.</gtr:title><gtr:parentPublicationTitle>Nanomedicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30e7e2fee983614ddb80b7213d567913"><gtr:id>30e7e2fee983614ddb80b7213d567913</gtr:id><gtr:otherNames>Sartain F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1743-5889</gtr:issn><gtr:outcomeId>5a8c1cbccc0a05.89802566</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BABC9589-6E49-40B5-A9F3-405AE977398C</gtr:id><gtr:title>Rapid &amp;quot;bottom-up&amp;quot; production of organic nanoparticles: From drug bioavailability enhancement to fluorescence studies of cellular accumulation</gtr:title><gtr:parentPublicationTitle>ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c531d7d54969cfc0ee4ded59357058a8"><gtr:id>c531d7d54969cfc0ee4ded59357058a8</gtr:id><gtr:otherNames>Rannard Steve P.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0065-7727</gtr:issn><gtr:outcomeId>56b33aa0c484b0.66773639</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E00EFBBB-37C8-461F-BB63-382C41D8425D</gtr:id><gtr:title>4th Annual Georgia Nanotechnology and Infectious Disease Symposium</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f1d0b33a9155ad878eeb3bfd94192bb"><gtr:id>5f1d0b33a9155ad878eeb3bfd94192bb</gtr:id><gtr:otherNames>Steve  Rannard (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>m_1226631533140763a4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9CA2B76-26B1-4D78-8AF3-DB1467A491A6</gtr:id><gtr:title>Partial mitigation of gold nanoparticle interactions with human lymphocytes by surface functionalization with a 'mixed matrix'.</gtr:title><gtr:parentPublicationTitle>Nanomedicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/936be8fe289660558eed2b8dc4f61ee3"><gtr:id>936be8fe289660558eed2b8dc4f61ee3</gtr:id><gtr:otherNames>Liptrott NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1743-5889</gtr:issn><gtr:outcomeId>545e308e906ab7.65079216</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F6269A0-9F9A-4318-984E-F608A86288A0</gtr:id><gtr:title>INVITED: Future direction and opportunities of nanomedicine and nanodrug delivery systems'</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/48459838935911b680e4543a7fab9f6d"><gtr:id>48459838935911b680e4543a7fab9f6d</gtr:id><gtr:otherNames>Rannard S P</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>545e77dce20713.11572302</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E45AF8B-8E5A-433B-A3C3-F4CCC7B8B202</gtr:id><gtr:title>Towards a rational design of solid drug nanoparticles with optimised pharmacological properties.</gtr:title><gtr:parentPublicationTitle>Journal of interdisciplinary nanomedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/65da67b16bc5ccd9ce1b330b734b99ed"><gtr:id>65da67b16bc5ccd9ce1b330b734b99ed</gtr:id><gtr:otherNames>Siccardi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2058-3273</gtr:issn><gtr:outcomeId>58c920a33d0206.08933203</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69C7B3B0-DFC2-426F-9535-FE21C8DB4716</gtr:id><gtr:title>Polydendrons: New branched dendritic-linear hybrid materials</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/48459838935911b680e4543a7fab9f6d"><gtr:id>48459838935911b680e4543a7fab9f6d</gtr:id><gtr:otherNames>Rannard S P</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>545e822da89f71.11700203</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FCEA7266-E4DC-45EE-8446-E41B10256115</gtr:id><gtr:title>Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics.</gtr:title><gtr:parentPublicationTitle>Therapeutic delivery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aba5e9bae9a56a3e6b33f6cf48ec89fa"><gtr:id>aba5e9bae9a56a3e6b33f6cf48ec89fa</gtr:id><gtr:otherNames>Tatham LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-5990</gtr:issn><gtr:outcomeId>56b31ae35667f7.86685003</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15DA9D67-A068-45C1-AC4B-89248B6844E5</gtr:id><gtr:title>In vitro characterization of efavirenz-containing solid drug nanoparticles</gtr:title><gtr:parentPublicationTitle>ANTIVIRAL THERAPY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/151899c7dd6c7ddeaac6bd47d81d2efa"><gtr:id>151899c7dd6c7ddeaac6bd47d81d2efa</gtr:id><gtr:otherNames>King S. C.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>56b33a9c917910.85958336</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC754E39-92B2-45BD-9817-105445C6DC91</gtr:id><gtr:title>Rapid &amp;quot;bottom-up&amp;quot; production of organic nanoparticles: From drug bioavailability enhancement to fluorescence studies of cellular accumulation</gtr:title><gtr:parentPublicationTitle>ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c531d7d54969cfc0ee4ded59357058a8"><gtr:id>c531d7d54969cfc0ee4ded59357058a8</gtr:id><gtr:otherNames>Rannard Steve P.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0065-7727</gtr:issn><gtr:outcomeId>56b33a9d3fc1f5.20394039</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C91D47F9-7AB2-42BC-804B-9D4FEF5FEAAF</gtr:id><gtr:title>High-throughput nanoprecipitation of the organic antimicrobial triclosan and enhancement of activity against Escherichia coli</gtr:title><gtr:parentPublicationTitle>Journal of Materials Chemistry B</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/722518fc75cb6d2dd93af953554f8a4f"><gtr:id>722518fc75cb6d2dd93af953554f8a4f</gtr:id><gtr:otherNames>McDonald T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>doi_55faa0aa0054aec0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C1E3405-FC4D-4CFC-9A45-678F69617A4F</gtr:id><gtr:title>Considerations for clinically-relevant nanomedicine therapies for chronic diseases.</gtr:title><gtr:parentPublicationTitle>Nanomedicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf1d6d619c42388d8cdb238501bb7319"><gtr:id>cf1d6d619c42388d8cdb238501bb7319</gtr:id><gtr:otherNames>Owen A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1743-5889</gtr:issn><gtr:outcomeId>56b31ae3f20457.21548573</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C5F008F-D17E-4BF1-A299-76E5239450A8</gtr:id><gtr:title>Beating HIV with a nanosized stick</gtr:title><gtr:parentPublicationTitle>Education in Chemistry -London-</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9160aacd1916e8ca6a9bbe0ac8e79e8"><gtr:id>c9160aacd1916e8ca6a9bbe0ac8e79e8</gtr:id><gtr:otherNames>Nina Notman (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>m_3607531263137ca14c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2BB688E-2990-46A9-80EE-DAC6FA8B865C</gtr:id><gtr:title>Augmented Inhibition of CYP3A4 in Human Primary Hepatocytes by Ritonavir Solid Drug Nanoparticles.</gtr:title><gtr:parentPublicationTitle>Molecular pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8aebd9fcdb75ba6a10430e6f39a62dd8"><gtr:id>8aebd9fcdb75ba6a10430e6f39a62dd8</gtr:id><gtr:otherNames>Martin P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1543-8384</gtr:issn><gtr:outcomeId>5675eb3a1c6ea</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17E1E171-6E7C-4461-9937-7A59138E1EA1</gtr:id><gtr:title>Nanoengineering</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/722518fc75cb6d2dd93af953554f8a4f"><gtr:id>722518fc75cb6d2dd93af953554f8a4f</gtr:id><gtr:otherNames>McDonald T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:isbn>9780444627476</gtr:isbn><gtr:outcomeId>56b31ae2d5a4d0.85162973</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2998FAEF-98CA-4F07-85CE-5B0397EB51D3</gtr:id><gtr:title>Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/236f8fefb1de42b371cef64a9fd83257"><gtr:id>236f8fefb1de42b371cef64a9fd83257</gtr:id><gtr:otherNames>Giardiello M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>58c90f6a0d1eb2.93407011</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15923201-A55A-4BEB-8773-1B706D41E9FD</gtr:id><gtr:title>Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacokinetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e855f713559d0f11c6dc4c71c220ac34"><gtr:id>e855f713559d0f11c6dc4c71c220ac34</gtr:id><gtr:otherNames>Rajoli RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0312-5963</gtr:issn><gtr:outcomeId>56b31ae331ea45.03151087</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/K002201/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>E847DD9B-2053-4BC7-97A9-4213B185C968</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Materials sciences</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>6723A70B-A523-40AB-9740-B6AD2A0677B7</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Medical &amp; health interface</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>B30DC286-3309-48E2-A15D-BDF547057A33</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Drug Formulation &amp; Delivery</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>561091A1-9FC9-4508-B1B2-2F3623E1FC9D</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Materials Characterisation</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>